Trials / Completed
CompletedNCT05372419
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab | Administered SC |
Timeline
- Start date
- 2023-01-12
- Primary completion
- 2024-05-03
- Completion
- 2025-02-17
- First posted
- 2022-05-12
- Last updated
- 2026-03-09
- Results posted
- 2025-06-11
Locations
36 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05372419. Inclusion in this directory is not an endorsement.